An autologous therapeutic dendritic cell vaccine transfected with total lung carcinoma rna stimulates cytotoxic t lymphocyte responses against non-small cell lung cancer

Immunological Investigations

Volumn 38, Issue 7, 2009, Pages 665-680

  Wang, Kun ^a   Zhou, Qing ^a   Guo, Ai Lin ^a   Xu, Chong Rui ^a   An, She Juan ^a   Wu, Yi Long ^a  

^a GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Dendritic cells; Lung carcinoma; Tumor immunity; Vaccine

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; DENDRITIC CELL VACCINE; LACTATE DEHYDROGENASE; MUCIN 1; RNA;

ADULT; AGED; ARTICLE; CELL STRUCTURE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; FEMALE; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE;

ADULT; AGED; CANCER VACCINES; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, NON-SMALL-CELL LUNG; CELL SURVIVAL; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; ELECTROPORATION; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LEUKOCYTES, MONONUCLEAR; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUCIN-1; RNA, NEOPLASM; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 70350701804     PISSN: 08820139     EISSN: 15324311     Source Type: Journal    
DOI: 10.1080/08820130903070528     Document Type: Article

References (35)

1. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature.1998;392:245-252
2. Bercovici N, Haicheur N, Massicard S, et al. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients. J Immunother. 2008; 31(1):101-112
3. Avigan DE, Vasir B, George DJ, et al. Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J Immunother. 2007;30(7): 749-761
4. Hildenbrand B, Sauer B, Kalis O, et al. Immunotherapy of patients with hormone-refractory prostate carcinoma pre-treated with interferon-gamma and vaccinated with autologous PSA-peptide loaded dendritic cells-a pilot study. Prostate. 2007;67(5):500-508
5. O'Mahony D, Kummar S, Gutierrez ME, et al. Non-small-cell lung cancer vaccine therapy: A concise review. J Clin Oncol. 2005;23(35):9022-9028
6. Sandra Tuyaerts, Joeri L. Aerts, Jurgen Corthals. Current approaches in dendritic cell generation and future implications for cancer immunotherapy. Cancer Immunol Immunother. 2007;56(10):1513-1537
7. Zeng G, Li Y, El-Gamil M, et al. Generation of NY-ESO-1-specific CD4+ and CD8+ T cells by a single peptide with dual MHC class I and class II specificities: A new strategy for vaccine design. Cancer Res. 2002;62:3630-3635.
8. Tacken PJ, Torensma R, Figdor CG. Targeting antigens to dendritic cells in vivo. Immunobiology. 2006;211:599-608.
9. Brichard VG, Lejeune D. Cancer immunotherapy targeting tumor-specific antigens: Towards a new therapy for minimal residual disease. Expert Opin Biol Ther. 2008;8(7):951-968
10. Ikeda H, Lethe B, Lehmann F, et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity. 1997;6(2):199-208.
11. Slingluff CL Jr, Colella TA, Thompson L, et al. Melanomas with concordant loss of multiple melanocytic differentiation proteins: Immune escape that may be overcome by targeting unique or undefined antigens. Cancer Immunol Immunother. 2000;48(12):661-672
12. Kerkmann-Tucek A, Banat GA, Cochlovius B, et al. Antigen loss variants of a murine renal cell carcinoma: Implications for tumor vaccination. Int J Cancer. 1998;77(1):114-122
13. Moore MW, Carbone FR, Bevan MJ. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell. 1988;54(6): 777-785
14. Paglia P, Chiodoni C, Rodolfo M, et al. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med. 1996;183(1):317-322
15. Ignatius R, Mahnke K, Rivera M, et al. Presentation of proteins encapsulated in sterically stabilized liposomes by dendritic cells initiates CD8(+) T-cell responses in vivo. Blood. 2000;96(10):3505-3513
16. Zhao X, Wei YQ, Peng ZL. Induction of T cell responses against autologous ovarian tumors with whole tumor cell lysate-pulsed dendritic cells. Immunol Invest. 2001;30(1):33-45.
17. Geiger J, Hutchinson R, Hohenkirk L, et al. Treatment of solid tumors in children with tumor-lysate-pulsed dendritic cells. Lancet. 2000;356:1163-1165
18. Hatfield P, Merrick AE, West E, et al. Optimization of dendritic cell loading with tumor cell lysates for cancer immunotherapy. J Immunother. 2008;31(7): 620-632
19. Sawabata N, Hirano H, Inoue M, et al. Immunohistochemical analysis of resected clinical stage I pulmonary adenocarcinomas with high preoperative levels of serum carcinoembryonic antigen. Ann Thorac Surg. 2003;76(1):203-207.
20. Wang K, Wu YL, Zhou Q, et al. Large-scale Generation of Mature Clinical Grade Dendritic Cells. Cancer Res Prevention Treatment. 2004;31(8):458-460.
21. Kalady MF, Onaitis MW, Padilla KM, et al. Enhanced dendritic cell antigen presentation in RNA-based immunotherapy. J Surg Res. 2002;105(1):17-24.
22. Mitchell DA, Nair SK. RNA-transfected dendritic cells in cancer immunotherapy. J Clin Invest. 2000;106(9): 1065-1069.
23. Bergant M, Meden L, Repnik U, et al. Preparation of native and amplified tumour RNA for dendritic cell transfection and generation of in vitro anti-tumour CTL responses. Immunobiology. 2006;211:179-189.
24. de Vries IJ, Lesterhuis WJ, Scharenborg NM, et al. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res. 2003;9(14):5091-5100
25. McIlroy D, Gregoire M. Optimizing dendritic cell-based anti-cancer immunotherapy: Maturation state does have clinical impact. Cancer Immunol Immunother. 2003;52:583-91.
26. Jarnjak-Jankovic S, Saebøe-Larssen S, Kvalheim G, et al. mRNA transfection of DC in the immature or mature state: Comparable in vitro priming of Th and cytotoxic T lymphocytes against DC electroporated with tumor cell line-derived mRNA. Cytotherapy. 2007;9(6):587-92.
27. Wolff JA, Malone RW, Williams P, et al. Direct gene transfer into mouse muscle in vivo. Science. 1990;247:1465-1468.
28. Nair SK, Boczkowski D, Morse M, et al. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat Biotechnol. 1998;16(4):364-369. (Pubitemid 28164657)
29. Van Tendeloo VF, Ponsaerts P, Lardon F, et al. Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood. 2001;98(1):49-56.
30. Lu D, Benjamin R, Kim M, et al. Optimization of methods to achieve mRNAmediated transfection of tumor cells in vitro and in vivo employing cationic liposome vectors. Cancer Gene Ther. 1994;1(4):245-252.
31. Okano K, Fukui M, Suehiro Y, et al. Evaluation of an mRNA lipofection procedure for human dendritic cells and induction of cytotoxic T lymphocytes against enhanced green fluorescence protein. Tumor Biol. 2003;24(6):317-324
32. Ponsaerts P, Van Tendeloo VF, Cools N, et al. mRNA-electroporated mature dendritic cells retain transgene expression, phonotypical properties and stimulatory capacity after cryopreservation. Leukemia, 2002;16(7):1324-1330.
33. Ponsaerts P, Van den Bosch G, Cools N, et al. Messenger RNA electroporation of human monocytes, followed by rapid in vitro differentiation, leads to highly stimulatory antigen-loaded mature dendritic cells. J Immunol. 2002;169(4):1669-1675.
34. Grünebach F, Müller MR, Brossart P. RNA transfection of dendritic cells. Methods Mol Med. 2005;109:47-54.
35. Michiels A, Tuyaerts S, Bonehill A, et al. Delivery of tumor-antigen-encoding mRNA into dendritic cells for vaccination. Methods Mol Biol. 2008;423:155-163